CFD 属于复杂的高风险金融工具，其杠杆作用可能导致投资者迅速亏损。 84% 的散户投资者因进行 CFD 交易遭受资金损失。 请您谨慎考虑自己是否了解 CFD 操作，以及是否能够接受高额亏损的风险。
Country • United States
    Entity • country not supported, please select another country
    English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文

    交易 Spero Therapeutics, Inc. - SPRO CFD

    -
    0%
    • 概括
    • 历史数据
    • 活动
    • 收入报表
    • 资产负债表
    • 现金流
    • 所有权
    交易条件
    价差 -
    多头隔夜费

    Long position overnight fee

    Margin. Your investment $1,000.00
    隔夜费用 -0.024874 %
    Charges from borrowed part ($-0.99)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    前往平台
    		-0.024874%
    空头隔夜费

    Short position overnight fee

    Margin. Your investment $1,000.00
    隔夜费用 0.002651 %
    Charges from borrowed part ($0.11)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    前往平台
    		0.002651%
    隔夜费时间 21:00 (UTC)
    最小交易量 1
    货币 USD
    保证金 20%
    上市交易所 United States of America
    交易费 0%

    *Information provided by Capital.com

    关键数据
    前收盘价* N/A
    开盘价* N/A
    1 年变化* N/A
    日范围* N/A
    52 周范围 0.68-9.00
    平均交易量（10 天） 432.79K
    平均交易量（3 个月) 9.27M
    市值 69.90M
    市盈率 -100.00K
    流通股 51.78M
    收入 8.81M
    EPS -3.11
    股息（收益率 %） N/A
    贝塔 0.89
    下一个财报发布日期 Mar 30, 2023

    所有数据都是由Refinitiv提供的， 除了标有星号的数据， 这是*由 Capital.com 提供的数据

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date 平倉 Change Change (%) 開倉 High Low

    Spero Therapeutics, Inc. Events

    時間（協調世界時） (UTC) 國家 事件
    No events scheduled
    查看所有活動
    • 年度
    • 每季度
    2021 2020 2019 2018 2017
    总收入 18.256 9.33 18.147 3.966 1.979
    收入 18.256 9.33 18.147 3.966 1.979
    总营业费用 106.227 88.443 81.363 46.772 43.709
    销售/一般/行政费用，总计 41.701 21.44 15.588 12.887 10.84
    研究与开发 64.526 67.003 65.775 33.885 32.869
    营业收入 -87.971 -79.113 -63.216 -42.806 -41.73
    利息收入（费用），非经营净值 -1.39 0.401 1.551 0 1.541
    其他，净值 -0.395 0.432 0.74 1.144 0.303
    税前净收入 -89.756 -78.28 -60.925 -41.662 -39.886
    税后净收入 -89.756 -78.28 -60.925 -41.662 -39.886
    少数股东权益 0 1.143
    未计算非常项目前的净收益 -89.756 -78.28 -60.925 -41.662 -38.743
    净收入 -89.756 -78.28 -60.925 -41.662 -38.743
    Total Adjustments to Net Income 0 -0.549 0 -7.354
    普通股股东可获收益 (不含非经常性项目) -89.756 -78.829 -60.925 -41.662 -46.097
    普通股股东可获收益 (含非經常性項目) -89.756 -78.829 -60.925 -41.662 -46.097
    摊薄调整
    摊薄净收入 -89.756 -78.829 -60.925 -41.662 -46.097
    摊薄后加权平均股 30.8958 22.3861 18.1605 16.0018 14.3692
    扣除特别项目的每股摊薄盈利 -2.90512 -3.52133 -3.3548 -2.60358 -3.20805
    Dividends per Share - Common Stock Primary Issue
    每股正常摊薄盈利 -2.90512 -3.52133 -3.3548 -2.60358 -3.20805
    非常规项目总计 0 0
    Sep 2022 Jun 2022 Mar 2022 Dec 2021 Sep 2021
    总收入 2.006 1.993 2.069 2.744 3.064
    收入 2.006 1.993 2.069 2.744 3.064
    总营业费用 13.84 31.654 32.276 30.246 25.588
    销售/一般/行政费用，总计 6.632 8.051 15.305 13.021 11.152
    研究与开发 7.36 8.173 16.971 17.225 14.436
    营业收入 -11.834 -29.661 -30.207 -27.502 -22.524
    利息收入（费用），非经营净值 0.182 0.989 -2.609 -1.66 0.09
    其他，净值 -0.023 -0.01 -0.013 -0.078 -0.087
    税前净收入 -11.675 -28.682 -32.829 -29.24 -22.521
    税后净收入 -11.675 -28.682 -32.829 -29.24 -22.521
    未计算非常项目前的净收益 -11.675 -28.682 -32.829 -29.24 -22.521
    净收入 -11.675 -28.682 -32.829 -29.24 -22.521
    普通股股东可获收益 (不含非经常性项目) -11.675 -28.682 -32.829 -29.24 -22.521
    普通股股东可获收益 (含非經常性項目) -11.675 -28.682 -32.829 -29.24 -22.521
    摊薄净收入 -11.675 -28.682 -32.829 -29.24 -22.521
    摊薄后加权平均股 35.8821 32.9778 32.6067 32.3311 32.1325
    扣除特别项目的每股摊薄盈利 -0.32537 -0.86974 -1.00682 -0.90439 -0.70088
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    每股正常摊薄盈利 -0.32961 -0.40185 -1.00682 -0.90439 -0.70088
    Total Adjustments to Net Income 0 0
    异常费用（收入） -0.152 15.43
    • 年度
    • 每季度
    2021 2020 2019 2018 2017
    流动资产总额 157.872 139.145 95.414 124.219 92.059
    现金和短期投资 146.402 126.906 82.045 115.443 87.288
    现金等价物 112.584 85.209 29.73 34.08 87.288
    应收账款总额，净额 2.641 6.176 8.546 1.298 2.943
    Prepaid Expenses 8.829 6.063 4.823 7.478 1.828
    Total Assets 171.072 153.451 106.103 129.006 93.479
    Property/Plant/Equipment, Total - Net 7.556 8.783 7.148 2.893 1.164
    Property/Plant/Equipment, Total - Gross 10.436 11.059 8.663 3.72 1.807
    Accumulated Depreciation, Total -2.88 -2.276 -1.515 -0.827 -0.643
    Note Receivable - Long Term 0 0.311 0.021 0.233 0
    Other Long Term Assets, Total 5.644 5.212 3.52 1.661 0.256
    Total Current Liabilities 18.67 14.343 26.663 12.318 8.157
    Accounts Payable 1.101 1.155 4.147 3.603 3.47
    Accrued Expenses 15.712 13.188 22.516 8.263 4.321
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 1.857 0 0.452 0.366
    Total Liabilities 82.783 21.411 31.529 13.506 8.877
    Total Long Term Debt 48.414 0 0 0 0
    Minority Interest 0.355 0.355
    Other Liabilities, Total 15.699 7.068 4.866 0.833 0.365
    Total Equity 88.289 132.04 74.574 115.5 84.602
    Redeemable Preferred Stock 0 0
    Common Stock 0.032 0.029 0.019 0.017 0.014
    Additional Paid-In Capital 455.719 409.722 273.966 254.013 181.428
    Retained Earnings (Accumulated Deficit) -367.463 -277.707 -199.427 -138.502 -96.84
    Total Liabilities & Shareholders’ Equity 171.072 153.451 106.103 129.006 93.479
    Total Common Shares Outstanding 32.3937 29.2603 19.1907 17.206 14.3692
    短期投资 33.818 41.697 52.315 81.363
    Other Equity, Total -0.002 -0.007 0.016 -0.028
    Preferred Stock - Non Redeemable, Net 0.003 0.003
    Total Preferred Shares Outstanding 3.21815 3.21829
    Long Term Debt 48.414
    Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
    流动资产总额 132.704 157.872 131.769 106.316 129.492
    现金和短期投资 121.966 146.402 123.417 99.218 115.676
    现金等价物 72.111 112.584 112.859 71.562 77.042
    短期投资 49.855 33.818 10.558 27.656 38.634
    应收账款总额，净额 1.991 2.641 2.584 2.197 8.622
    Prepaid Expenses 8.747 8.829 5.768 4.901 5.194
    Total Assets 145.83 171.072 144.691 119.594 143.44
    Property/Plant/Equipment, Total - Net 7.197 7.556 7.71 8.067 8.425
    Note Receivable - Long Term 0 0 0 0.311
    Other Long Term Assets, Total 5.929 5.644 5.212 5.211 5.212
    Total Current Liabilities 69.199 18.67 17.258 12.826 17.763
    Accounts Payable 4.78 1.101 3.161 1.632 3.825
    Accrued Expenses 10.429 15.712 12.398 10.015 13.938
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 83.357 82.783 32.796 29.342 24.594
    Total Long Term Debt 0 48.414 0 0 0
    Other Liabilities, Total 14.158 15.699 15.538 16.516 6.831
    Total Equity 62.473 88.289 111.895 90.252 118.846
    Preferred Stock - Non Redeemable, Net 0.003 0.003 0.003 0.003 0.003
    Common Stock 0.033 0.032 0.032 0.03 0.03
    Additional Paid-In Capital 462.735 455.719 450.085 405.923 415.946
    Retained Earnings (Accumulated Deficit) -400.292 -367.463 -338.223 -315.702 -297.13
    Other Equity, Total -0.006 -0.002 -0.002 -0.002 -0.003
    Total Liabilities & Shareholders’ Equity 145.83 171.072 144.691 119.594 143.44
    Total Common Shares Outstanding 32.7556 32.3937 32.2203 29.6992 29.6639
    Total Preferred Shares Outstanding 3.21815 3.21815 3.21815 3.21815 3.21815
    Other Current Liabilities, Total 53.99 1.857 1.699 1.179
    Long Term Debt 0 48.414
    • 年度
    • 每季度
    2021 2020 2019 2018 2017
    净收入/起跑线 -89.756 -78.28 -60.925 -41.662 -39.886
    经营活动产生的现金 -64.347 -85.872 -50.02 -39.625 -39.111
    经营活动产生的现金 0.646 0.761 0.75 0.409 0.363
    非现金物品 11.901 5.111 3.376 2.699 -0.031
    营运资金的变化 12.862 -13.464 6.779 -1.071 0.443
    投资活动产生的现金 7.672 10.47 29.53 -83.156 -0.027
    资本支出 -0.157 -0.314 -2.436 -0.027
    融资活动产生的现金 84.05 130.881 16.14 69.523 116.111
    融资现金流项目 47.232 -0.953 -0.158 -1.312 -4.749
    股票的发行（报废），净额 36.818 131.834 16.298 70.835 120.86
    现金净变化 27.375 55.479 -4.35 -53.258 76.973
    其他投资现金流量项目，总计 7.672 10.627 29.844 -80.72
    Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
    Net income/Starting Line -32.829 -89.756 -60.516 -37.995 -19.423
    Cash From Operating Activities -28.223 -64.347 -36.998 -32.046 -15.479
    Cash From Operating Activities 0.189 0.646 0.455 0.307 0.159
    Non-Cash Items 6.117 11.901 7.327 4.708 2.253
    Changes in Working Capital -1.7 12.862 15.736 0.934 1.532
    Cash From Investing Activities -16.064 7.672 30.947 13.922 3.003
    Other Investing Cash Flow Items, Total -16.064 7.672 30.947 13.922 3.003
    Cash From Financing Activities 3.814 84.05 33.701 4.477 4.309
    Financing Cash Flow Items 0 47.232 -0.411 -0.146 -0.037
    Issuance (Retirement) of Stock, Net 3.814 36.818 34.112 4.623 4.346
    Net Change in Cash -40.473 27.375 27.65 -13.647 -8.167
    Capital Expenditures 0 0
    投资者名称 投资者类型 流通股百分比 持有股份 股份变动 持有日期 换手率
    GSK plc Corporation 17.7507 9190606 7450000 2022-11-14 MED
    Anson Funds Management LP. Hedge Fund 5.8321 3019608 1545736 2022-12-31 HIGH
    Atlas Venture Venture Capital 4.651 2408128 0 2022-12-31 LOW
    Pfizer Inc Corporation 4.5626 2362348 0 2022-07-20 MED
    AWM Investment Company, Inc. Investment Advisor/Hedge Fund 2.5116 1300400 -1000000 2022-12-31 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.0364 1054388 665 2022-12-31 LOW
    Alphabet, Inc. Venture Capital 1.7189 889979 0 2022-12-31 LOW
    Millennium Management LLC Hedge Fund 1.6927 876398 188002 2022-12-31 HIGH
    Murchinson Ltd. Investment Advisor/Hedge Fund 1.4731 762700 0 2022-12-31 HIGH
    Rock Springs Capital Management LP Hedge Fund 1.2931 669533 -101177 2022-12-31 LOW
    Mahadevia (Ankit) Individual Investor 1.1307 585445 519628 2023-02-03 MED
    BlackRock Institutional Trust Company, N.A. Investment Advisor 0.9252 479031 -187473 2022-12-31 LOW
    Hamed (Kamal) Individual Investor 0.9193 475957 265957 2023-02-01 MED
    Novo Holdings A/S Venture Capital 0.9056 468902 0 2022-12-31 LOW
    XTX Markets LLC Investment Advisor 0.6697 346734 346734 2022-12-31 HIGH
    Renaissance Technologies LLC Hedge Fund 0.6623 342900 128200 2022-12-31 HIGH
    Keutzer (Timothy) Individual Investor 0.6318 327144 262563 2023-02-02 LOW
    Joseph (Tamara) Individual Investor 0.627 324644 262563 2023-02-02 LOW
    Oasis Management Company Ltd. Investment Advisor/Hedge Fund 0.5562 288000 0 2022-12-31 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.4969 257284 -32974 2022-12-31 LOW

    为什么选择 Capital.com？让我们的数字来说话。

    Capital.com Group

    500K+

    交易者

    92K+

    每月活跃客户

    $53M+

    每月投资额

    $30M+

    每月提取金额

    交易計算器

    如果您在特定日期（选择一个日期）开立差价合约交易并在不同日期（选择一个日期）关闭交易，计算您的假设盈亏。

    貿易佣金
    0
    • 1:1
    杠杆
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    投資
    交易規模（槓桿 x 投資）：
    開倉

    平倉

    做空 做多
    過去的表現並不是未來結果的可靠指標
    盈利/失利

    Spero Therapeutics, Inc. Company profile

    关于 Spero Therapeutics Inc.

    Spero Therapeutics, Inc.是一家处于临床阶段的生物制药公司。 该公司专注于识别、开发和商业化治疗MDR细菌感染的新型疗法。 其主要候选产品tebipenem HBr（tebipenem pivoxil hydrobromide）被开发为口服碳青霉烯类抗生素，用于治疗复杂尿路感染（cUTI）和急性肾盂肾炎（AP）。 该公司还在开发SPR720，作为一种新型口服治疗候选产品，用于治疗由非结核分枝杆菌（NTM）感染引起的罕见的孤儿肺部疾病。 公司还有一个从其增效剂平台开发的静脉注射的下一代多粘菌素候选产品SPR206，该产品正在开发用于治疗医院环境中的MDR革兰氏阴性感染。

    Industry: Bio Therapeutic Drugs

    675 Massachusetts Ave Ste 14
    CAMBRIDGE
    MASSACHUSETTS 02139-3309
    US

    收入报表

    • Annual
    • Quarterly

    人们也观看

    US100

    12,977.80 Price
    +1.070% 1D Chg, %
    多头隔夜费 -0.0249%
    空头隔夜费 0.0027%
    隔夜费时间 21:00 (UTC)
    价差 1.8

    Gold

    1,981.10 Price
    +0.860% 1D Chg, %
    多头隔夜费 -0.0180%
    空头隔夜费 0.0098%
    隔夜费时间 21:00 (UTC)
    价差 0.30

    XRP/USD

    0.54 Price
    -2.490% 1D Chg, %
    多头隔夜费 -0.0753%
    空头隔夜费 0.0069%
    隔夜费时间 21:00 (UTC)
    价差 0.00421

    Oil - Crude

    74.45 Price
    +2.140% 1D Chg, %
    多头隔夜费 -0.0170%
    空头隔夜费 -0.0049%
    隔夜费时间 21:00 (UTC)
    价差 0.03

    还在找一位您可以信任的经纪商吗？

    加入成为全球500,000万多名交易者的一份子，选择利用Capital.com进行交易吧。

    1. 创建和验证您的账户 2. 进行存款 3. 找到适合您的交易